Developer docs
API playgroundTry for free, no card

Search company profiles

PanTera

Full company profile

uuid0000ce6

Namestring
PanTera
Legal namestring
PanTera nv
Company typeenum
Private
Founded yearint
2022
Descriptiontext

PanTera is a Belgian joint venture founded in September 2022 by IBA (Ion Beam Applications S.A.) and SCK CEN (Belgian Nuclear Research Centre) to produce actinium-225 (Ac-225), an alpha-emitting radioisotope used in targeted alpha therapy (TAT) for cancer treatment. The company addresses a documented global shortage of high-purity Ac-225 that has constrained pharmaceutical development of Ac-225-based radiopharmaceuticals. Its headquarters and production site are located at Boeretang 192 in Mol, Belgium, on SCK CEN's premises.

PanTera operates a dual supply strategy. The Early Supply Program, which delivered its first Ac-225 extraction in June 2025, uses Thorium-229 (Th-229) generators sourced through a strategic collaboration with TerraPower Isotopes. The commercial-scale Actinium Production Center (APC), currently under construction with groundbreaking in October 2025 and expected operational by 2028, employs a photonuclear (gamma) production route: Radium-226 is irradiated using an IBA Rhodotron electron beam accelerator (40 MeV, up to 125 kW) to produce Ra-225, which decays into high-purity Ac-225. The proprietary process avoids Ac-227 contamination associated with thorium spallation routes. Licensed-in intellectual property from IBA and SCK CEN — covering radiochemical processing, radon abatement, electron-gamma conversion, radium targetry, and waste handling — underpins the technology stack.

The business model is B2B enterprise supply: PanTera sells clinical-grade Ac-225 as an Active Product Ingredient (API) to pharmaceutical and biotech companies developing Ac-225-based radiopharmaceuticals. Confirmed customers include Bayer and SK Biopharmaceuticals, with the broader segment also referencing Bristol Myers Squibb, AstraZeneca, and Eli Lilly. Pricing is not publicly disclosed; agreements are long-term direct supply contracts. The company targets production of more than 100 Curies of Ac-225 annually by 2029, sufficient to treat approximately 100,000 patients per year. Total funding raised to date is EUR 134 million, comprising a EUR 93 million oversubscribed Series A led by EQT Life Sciences in September 2024 plus additional equity and debt.

Short descriptiontext

PanTera is a Belgian joint venture of IBA and SCK CEN that produces actinium-225 (Ac-225) as an Active Product Ingredient for pharmaceutical companies developing targeted alpha therapy radiopharmaceuticals for cancer treatment.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMol, Belgium
HQ citystring
Mol
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
actinium-225 production, medical radioisotope supply, radiopharmaceutical manufacturing, targeted alpha therapy, nuclear medicine isotopes
Industry3 codes
PRIMARYHLAIAGAD
Radioisotope Production (Reactor/Cyclotron/Gamma)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYEUAKAIAA
Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
SECONDARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Medical Radioisotope Production
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Actinium-225 API Supply
TypeTransaction Fee
Description

PanTera supplies high-purity actinium-225 as an Active Product Ingredient (API) to pharmaceutical companies developing radiopharmaceutical cancer therapies. Revenue is generated through supply agreements with drug developers, providing clinical-grade Ac-225 for targeted alpha therapy applications.

pantera-life.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Infrastructure, Personnel, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

PanTera manufactures and supplies high-purity actinium-225 (Ac-225), an alpha-emitting radioisotope used as an Active Product Ingredient (API) in targeted alpha therapy (TAT) radiopharmaceuticals for cancer treatment. The company produces Ac-225 via a proprietary photonuclear (gamma) route using Radium-226 processed with an IBA Rhodotron accelerator, and supplements this with an early supply program using Thorium-229 generators, serving pharmaceutical companies developing Ac-225-based radiopharmaceuticals globally.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 100,000 patients annually by 2029
+1 more record
Product overview1 text field

PanTera is a joint venture between IBA and SCK CEN focused on large-scale production of actinium-225 (Ac-225), a critical alpha-emitting radioisotope for targeted cancer therapies. The company operates a dual supply strategy: an Early Supply Program using Thorium-229 generators (operational since 2024) and a commercial-scale Actinium Production Center (APC) using the photonuclear (gamma) production route from Radium-226, expected to produce over 100 Curies annually by 2029. The company's production facility in Mol, Belgium, powered by IBA's Rhodotron technology, aims to address the global shortage of Ac-225 and enable widespread availability of radiopharmaceutical therapies for cancer treatment.

Product and service2 records
1Actinium-225 (Ac-225) API
CategoryMedical Radioisotope Production
Description

High-purity actinium-225 (Ac-225) supplied as a clinical-grade Active Product Ingredient (API) for pharmaceutical and biotech companies developing targeted alpha therapy (TAT) radiopharmaceuticals for cancer treatment. Ac-225 emits alpha particles that destroy cancer cells while minimizing damage to nearby healthy tissue.

2Early Supply Program
CategoryMedical Radioisotope Supply Service
Description

Supply program providing early access to actinium-225 (Ac-225) produced via Thorium-229 (Th-229) generators while the commercial Actinium Production Center is under construction. Thorium-229 decays to Ra-225 and then to Ac-225, which is extracted for delivery to pharmaceutical customers.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-05-27
Description

IRE, supported by TerraPower Isotopes and PanTera, expanded collaboration to boost global actinium-225 supply. New facilities in Belgium will bolster production efforts for the critical isotope in next-generation cancer treatment.

2SK Biopharmaceuticals
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-02-25
Description

SK Biopharmaceuticals signed a collaboration with PanTera for the supply of actinium-225. SK Biopharmaceuticals is developing an Ac-225-based radiopharmaceutical therapy candidate (SKL35501) for advanced solid tumors expressing NTSR1.

pantera-life.com
Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2024-03-28
Description

Tractebel combined its infrastructure and nuclear expertise with Modulo architects to support the design and construction of PanTera's actinium-225 production facility in Belgium.

Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2024-03-28
Description

Modulo architects partnered with Tractebel to design PanTera's medical radioisotope production facility in Belgium.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-02-12
Description

Bayer signed a supply agreement with PanTera for actinium-225, demonstrating PanTera's ability to support the radionuclide therapeutics industry in bringing new cancer treatments to patients.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-06-26
Description

Strategic collaboration providing PanTera with Thorium-229 material for a generator that produces actinium-225. TerraPower Isotopes supplies Th-229 which naturally decays to Ra-225 and then Ac-225, enabling early supply production starting 2024. Expanded collaboration in 2026 with IRE support to boost global supply.

7IBA
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-09-22
Description

IBA (Ion Beam Applications S.A.) is a joint venture partner and world leader in particle accelerator technology. IBA provides the Rhodotron technology and has transferred proprietary IP including radiochemical processing methods, electron-gamma converter system, and radium targetry to PanTera.

pantera-life.com
8SCK CEN
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-09-22
Description

SCK CEN (Belgian Nuclear Research Centre) is a joint venture partner with 70 years of nuclear research experience. SCK CEN provides privileged access to high-purity radium-226 and related handling expertise, and has transferred proprietary IP including radiochemical processing methods, radon abatement system, and waste handling to PanTera.

pantera-life.com
Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Subsidiary of TerraPower focused on medical isotope production. Both companies supply Ac-225 via different production routes (Th-229 decay for TerraPower, photonuclear gamma for PanTera), making them strategic partners and direct competitors for the same pharmaceutical off-takers.

TypeDirect peer
Description

Belgium-based global leader in radioisotope production for medical and industrial use (Mo-99, I-131, Lu-177, Xe-133). Recently expanded collaboration with PanTera/TerraPower for global Ac-225 supply; competes for radiopharma manufacturer contracts across overlapping product lines.

TypeDirect peer
Description

Germany-based medical radioisotope producer with a vertically integrated radiopharmaceutical pipeline. Produces Lu-177, Y-90, and other medical isotopes and is expanding into alpha emitters — directly comparable to PanTera as a medical isotope API supplier serving global pharma.

TypeBroad incumbent
Description

World's largest nuclear medicine company, producing a broad portfolio of diagnostic and therapeutic radiopharmaceuticals (SPECT/PET tracers, I-131, Lu-177). Established incumbent competing for the same pharmaceutical off-take relationships that PanTera targets with its Ac-225 supply.

TypeDirect peer
Description

German manufacturer and distributor of radioisotopes and radiation technology for medical, scientific, and industrial use. Produces medical isotopes including therapeutic radioisotopes and competes in the same API supply market as PanTera.

TypeDirect peer
Description

US-based commercial producer of medical radioisotopes (primarily Mo-99/Tc-99m) using novel non-reactor production routes. Closely comparable technology positioning to PanTera's non-traditional production approach and target end-market of pharmaceutical companies developing radiopharmaceuticals.

TypeEmerging player
Description

Commercial-stage radiopharmaceutical company developing diagnostic and therapeutic products using Ac-225, Lu-177, and other isotopes. Represents both a potential customer of PanTera's Ac-225 supply and a downstream competitor in the radiopharmaceutical value chain.

TypeBroad incumbent
Description

Major pharmaceutical company with commercial radioligand therapy portfolio (Lutathera, Pluvicto) primarily using Lu-177. Represents the largest end-market for therapeutic radioisotope APIs and a potential customer for PanTera's Ac-225 as next-generation TAT expands.

TypeBroad incumbent
Description

Acquired Point Biopharma in 2023 for its Ac-225 and Lu-177 radioligand therapy pipeline. Represents both a major potential customer of PanTera's Ac-225 supply and a competitive threat via internal isotope production capabilities.

10IBA (Ion Beam Applications)
TypeOthers
Description

Parent company of PanTera and world leader in particle accelerator technology (including the Rhodotron). Provides enabling technology to PanTera but operates as a separate entity selling accelerators globally to other isotope producers and radiotherapy centers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PanTera

Medical Radioisotope Productionpantera-life.com

PanTera is a Belgian joint venture of IBA and SCK CEN that produces actinium-225 (Ac-225) as an Active Product Ingredient for pharmaceutical companies developing targeted alpha therapy radiopharmaceuticals for cancer treatment.

What PanTera does

PanTera is a Belgian joint venture founded in September 2022 by IBA (Ion Beam Applications S.A.) and SCK CEN (Belgian Nuclear Research Centre) to produce actinium-225 (Ac-225), an alpha-emitting radioisotope used in targeted alpha therapy (TAT) for cancer treatment. The company addresses a documented global shortage of high-purity Ac-225 that has constrained pharmaceutical development of Ac-225-based radiopharmaceuticals. Its headquarters and production site are located at Boeretang 192 in Mol, Belgium, on SCK CEN's premises.

PanTera operates a dual supply strategy. The Early Supply Program, which delivered its first Ac-225 extraction in June 2025, uses Thorium-229 (Th-229) generators sourced through a strategic collaboration with TerraPower Isotopes. The commercial-scale Actinium Production Center (APC), currently under construction with groundbreaking in October 2025 and expected operational by 2028, employs a photonuclear (gamma) production route: Radium-226 is irradiated using an IBA Rhodotron electron beam accelerator (40 MeV, up to 125 kW) to produce Ra-225, which decays into high-purity Ac-225. The proprietary process avoids Ac-227 contamination associated with thorium spallation routes. Licensed-in intellectual property from IBA and SCK CEN — covering radiochemical processing, radon abatement, electron-gamma conversion, radium targetry, and waste handling — underpins the technology stack.

The business model is B2B enterprise supply: PanTera sells clinical-grade Ac-225 as an Active Product Ingredient (API) to pharmaceutical and biotech companies developing Ac-225-based radiopharmaceuticals. Confirmed customers include Bayer and SK Biopharmaceuticals, with the broader segment also referencing Bristol Myers Squibb, AstraZeneca, and Eli Lilly. Pricing is not publicly disclosed; agreements are long-term direct supply contracts. The company targets production of more than 100 Curies of Ac-225 annually by 2029, sufficient to treat approximately 100,000 patients per year. Total funding raised to date is EUR 134 million, comprising a EUR 93 million oversubscribed Series A led by EQT Life Sciences in September 2024 plus additional equity and debt.

PanTera firmographics

Firmographics
Name
PanTera
Legal name
PanTera nv
Website
https://pantera-life.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
51–100 employees
Short description
PanTera is a Belgian joint venture of IBA and SCK CEN that produces actinium-225 (Ac-225) as an Active Product Ingredient for pharmaceutical companies developing targeted alpha therapy radiopharmaceuticals for cancer treatment.
Ownership category
akta.pro rank

PanTera industry classification

Industry
Product category
Medical Radioisotope Production
NAICS
Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAGAD
Radioisotope Production (Reactor/Cyclotron/Gamma)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYEUAKAIAA
Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
SECONDARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine

Keywords

  • Actinium-225 production
  • Medical radioisotope supply
  • Radiopharmaceutical manufacturing
  • Targeted alpha therapy
  • Nuclear medicine isotopes

Where PanTera is headquartered

Location

Headquarters

HQ city
Mol
HQ country
Belgium
HQ region
Europe

Offices1 record

Markets served

PanTera business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Infrastructure, Personnel, Operations, Supply Chain

Revenue model

  1. Actinium-225 API Supply: PanTera supplies high-purity actinium-225 as an Active Product Ingredient (API) to pharmaceutical companies developing radiopharmaceutical cancer therapies. Revenue is generated through supply agreements with drug developers, providing clinical-grade Ac-225 for targeted alpha therapy applications.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

PanTera product offering

Product offering

Core offering

PanTera manufactures and supplies high-purity actinium-225 (Ac-225), an alpha-emitting radioisotope used as an Active Product Ingredient (API) in targeted alpha therapy (TAT) radiopharmaceuticals for cancer treatment. The company produces Ac-225 via a proprietary photonuclear (gamma) route using Radium-226 processed with an IBA Rhodotron accelerator, and supplements this with an early supply program using Thorium-229 generators, serving pharmaceutical companies developing Ac-225-based radiopharmaceuticals globally.

Product overview

PanTera is a joint venture between IBA and SCK CEN focused on large-scale production of actinium-225 (Ac-225), a critical alpha-emitting radioisotope for targeted cancer therapies. The company operates a dual supply strategy: an Early Supply Program using Thorium-229 generators (operational since 2024) and a commercial-scale Actinium Production Center (APC) using the photonuclear (gamma) production route from Radium-226, expected to produce over 100 Curies annually by 2029. The company's production facility in Mol, Belgium, powered by IBA's Rhodotron technology, aims to address the global shortage of Ac-225 and enable widespread availability of radiopharmaceutical therapies for cancer treatment.

Differentiator

Problem solved

Functional benefit

Products and services

  • Actinium-225 (Ac-225) API High-purity actinium-225 (Ac-225) supplied as a clinical-grade Active Product Ingredient (API) for pharmaceutical and biotech companies developing targeted alpha therapy (TAT) radiopharmaceuticals for cancer treatment. Ac-225 emits alpha particles that destroy cancer cells while minimizing damage to nearby healthy tissue.
  • Early Supply Program Supply program providing early access to actinium-225 (Ac-225) produced via Thorium-229 (Th-229) generators while the commercial Actinium Production Center is under construction. Thorium-229 decays to Ra-225 and then to Ac-225, which is extracted for delivery to pharmaceutical customers.

Quantifiable outcome

  • 100,000 patients annually by 2029
  • +1 more outcomes

Companies that use PanTera

Customer profile

Named customers2 records

Segments1 record

Ideal customer profiles1 record

PanTera technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

PanTera partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered minor and core.

  • IRE (Institut National des Radioéléments)minorStrategic or Co-development Partner · 27 May 2026IRE, supported by TerraPower Isotopes and PanTera, expanded collaboration to boost global actinium-225 supply. New facilities in Belgium will bolster production efforts for the critical isotope in next-generation cancer treatment.
  • SK BiopharmaceuticalscoreStrategic or Co-development Partner · 25 February 2025SK Biopharmaceuticals signed a collaboration with PanTera for the supply of actinium-225. SK Biopharmaceuticals is developing an Ac-225-based radiopharmaceutical therapy candidate (SKL35501) for advanced solid tumors expressing NTSR1.
  • TractebelminorImplementation/ SI/ Consulting Partner · 28 March 2024Tractebel combined its infrastructure and nuclear expertise with Modulo architects to support the design and construction of PanTera's actinium-225 production facility in Belgium.
  • Modulo architectsminorImplementation/ SI/ Consulting Partner · 28 March 2024Modulo architects partnered with Tractebel to design PanTera's medical radioisotope production facility in Belgium.
  • BayercoreStrategic or Co-development Partner · 12 February 2024Bayer signed a supply agreement with PanTera for actinium-225, demonstrating PanTera's ability to support the radionuclide therapeutics industry in bringing new cancer treatments to patients.
  • TerraPower IsotopescoreStrategic or Co-development Partner · 26 June 2023Strategic collaboration providing PanTera with Thorium-229 material for a generator that produces actinium-225. TerraPower Isotopes supplies Th-229 which naturally decays to Ra-225 and then Ac-225, enabling early supply production starting 2024. Expanded collaboration in 2026 with IRE support to boost global supply.
  • IBAcoreStrategic or Co-development Partner · 22 September 2022IBA (Ion Beam Applications S.A.) is a joint venture partner and world leader in particle accelerator technology. IBA provides the Rhodotron technology and has transferred proprietary IP including radiochemical processing methods, electron-gamma converter system, and radium targetry to PanTera.
  • SCK CENcoreStrategic or Co-development Partner · 22 September 2022SCK CEN (Belgian Nuclear Research Centre) is a joint venture partner with 70 years of nuclear research experience. SCK CEN provides privileged access to high-purity radium-226 and related handling expertise, and has transferred proprietary IP including radiochemical processing methods, radon abatement system, and waste handling to PanTera.

Scale indicators5 records

Recent moves9 records

Expansion highlights5 records

PanTera competitors and assessment

Company assessment

Direct peers

  • TerraPower Isotopes: Subsidiary of TerraPower focused on medical isotope production. Both companies supply Ac-225 via different production routes (Th-229 decay for TerraPower, photonuclear gamma for PanTera), making them strategic partners and direct competitors for the same pharmaceutical off-takers.
  • IRE (Institut National des Radioéléments): Belgium-based global leader in radioisotope production for medical and industrial use (Mo-99, I-131, Lu-177, Xe-133). Recently expanded collaboration with PanTera/TerraPower for global Ac-225 supply; competes for radiopharma manufacturer contracts across overlapping product lines.
  • ITM Isotope Technologies Munich: Germany-based medical radioisotope producer with a vertically integrated radiopharmaceutical pipeline. Produces Lu-177, Y-90, and other medical isotopes and is expanding into alpha emitters — directly comparable to PanTera as a medical isotope API supplier serving global pharma.
  • Eckert & Ziegler: German manufacturer and distributor of radioisotopes and radiation technology for medical, scientific, and industrial use. Produces medical isotopes including therapeutic radioisotopes and competes in the same API supply market as PanTera.
  • NorthStar Medical Radioisotopes: US-based commercial producer of medical radioisotopes (primarily Mo-99/Tc-99m) using novel non-reactor production routes. Closely comparable technology positioning to PanTera's non-traditional production approach and target end-market of pharmaceutical companies developing radiopharmaceuticals.

Broad incumbents

  • Curium Pharma: World's largest nuclear medicine company, producing a broad portfolio of diagnostic and therapeutic radiopharmaceuticals (SPECT/PET tracers, I-131, Lu-177). Established incumbent competing for the same pharmaceutical off-take relationships that PanTera targets with its Ac-225 supply.
  • Novartis (Radioligand Therapy): Major pharmaceutical company with commercial radioligand therapy portfolio (Lutathera, Pluvicto) primarily using Lu-177. Represents the largest end-market for therapeutic radioisotope APIs and a potential customer for PanTera's Ac-225 as next-generation TAT expands.
  • Eli Lilly (Point Biopharma): Acquired Point Biopharma in 2023 for its Ac-225 and Lu-177 radioligand therapy pipeline. Represents both a major potential customer of PanTera's Ac-225 supply and a competitive threat via internal isotope production capabilities.

Emerging players

  • Telix Pharmaceuticals: Commercial-stage radiopharmaceutical company developing diagnostic and therapeutic products using Ac-225, Lu-177, and other isotopes. Represents both a potential customer of PanTera's Ac-225 supply and a downstream competitor in the radiopharmaceutical value chain.

Others

  • IBA (Ion Beam Applications): Parent company of PanTera and world leader in particle accelerator technology (including the Rhodotron). Provides enabling technology to PanTera but operates as a separate entity selling accelerators globally to other isotope producers and radiotherapy centers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

PanTera social profiles

Digital presence

PanTera compliance and trust

Trust signal

Compliance3 records

PanTera financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PanTera leadership team

Management profile

Number of profiles

Profiles12 records

PanTera funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PanTera M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PanTera

What does PanTera do?

PanTera manufactures and supplies high-purity actinium-225 (Ac-225), an alpha-emitting radioisotope used as an Active Product Ingredient (API) in targeted alpha therapy (TAT) radiopharmaceuticals for cancer treatment. The company produces Ac-225 via a proprietary photonuclear (gamma) route using Radium-226 processed with an IBA Rhodotron accelerator, and supplements this with an early supply program using Thorium-229 generators, serving pharmaceutical companies developing Ac-225-based radiopharmaceuticals globally.

Is PanTera a public or private company?

PanTera is a private company. It is classified as venture growth investor backed and is currently operating.

When was PanTera founded?

PanTera was founded in 2022. It employs 51 to 100 people.

Where is PanTera based?

PanTera is headquartered in Mol, Belgium, in the Europe region.

How does PanTera make money?

One revenue line is on record: actinium-225 API Supply.

Who are PanTera's main competitors?

Direct peers on record are TerraPower Isotopes, IRE (Institut National des Radioéléments), ITM Isotope Technologies Munich, Eckert & Ziegler and NorthStar Medical Radioisotopes. Broad incumbents are Curium Pharma, Novartis (Radioligand Therapy) and Eli Lilly (Point Biopharma). Telix Pharmaceuticals is listed as an emerging player. IBA (Ion Beam Applications) is listed as an others.

Does PanTera have an API?

No public API is recorded for PanTera.

What industry is PanTera in?

PanTera's product category is Medical Radioisotope Production. Its primary akta.pro industry code is HLAIAGAD, Radioisotope Production (Reactor/Cyclotron/Gamma), with a secondary code of EUAKAIAA, Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.). Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpace/C O R R E C T I O N -- Ratio Therapeutics Inc./Ratio Therapeutics entered a strategic supply agreement with PanTera to secure Actinium-225 for its radiopharmaceutical development programs. The agreement provides dedicated Ac-225 supply and a framework for future expansion, supporting its clinical-stage radiotherapeutic programs. PanTera's production strategy includes early supply by 2025 and commercial supply by 2028.DOTmedTerraPower Isotopes, PanTera expand partnership to increase actinium-225 productionTerraPower Isotopes and PanTera expanded their partnership to increase actinium-225 production, with a new line at IRE in Fleurus, Belgium. The move is expected to increase PanTera's cGMP-compliant Ac-225 capacity by over 200%, with the new line operational within 18 months.BioSpaceFirst quarter 2026 update: starting the year on track, with product innovation progressIBA reported Q1 2026 results with a stable €1.6 billion backlog and reaffirmed FY2026 adjusted EBIT guidance of at least €32 million. Commercial momentum was driven by RadioPharma Solutions, while Proton Therapy had 42 projects in backlog and 9 installations underway. The company expects net financial position to improve in H2 2026.EIN PresswirePantera’s EnergyX Stake Re-Rated to A$42.6 Million Following Increase in Capital Raise PricePantera Minerals re-rated its EnergyX stake to A$42.6 million after EnergyX's capital raise price rose to US$13 per share. The 2.34 million shareholding is up A$8.6 million from its original A$34 million value, a 37% increase. EnergyX has raised about US$170 million and commissioned a Texas demonstration plant.ABN NewswirePantera Minerals Limited (ASX:PFE) High-Grade Antimony to 3.9% Sb and Extensive Soil Anomalies Confirm Priority Drill TargetsPantera Minerals Limited has received results from the first modern exploration program at its 100%-owned Gillham project in southwest Arkansas, with rock chip sampling identifying high-grade antimony up to 3.92% Sb along with significant silver, gold, and base metal mineralization across multiple prospects. The soil sampling program defined strong antimony anomalism with peak values of 2,660ppm Sb and identified two coherent coincident Sb-As-Zn-Pb anomalies (~400m and ~500m strike) as high-priority drill targets. The company is advancing toward a maiden drilling program, which it expects will be a key value inflection point.PanewslabFounders Fund、Pantera与Franklin Templeton加入Sentient的 “Arena”,对企业级AI智能体进行压力测试Open-source AI lab Sentient has launched Arena, a production-grade testing environment for enterprise AI agents, with Founders Fund, Pantera, and Franklin Templeton ($1.5T+ AUM) joining as initial participants to stress-test AI reasoning in high-stakes workflows. The platform addresses a critical gap: while 85% of enterprises aspire to become 'agentic enterprises,' fewer than a quarter have mature governance frameworks, and many struggle to scale pilots beyond isolated deployments. Arena will simulate real-world operational chaos—including incomplete information, long contexts, ambiguous instructions, and conflicting sources—to provide vendor-agnostic benchmarks for production reliability.CoinDeskPantera leads $11.5M round in Based, a Hyperliquid-powered crypto appBased, a Web3 consumer app for trading and spending crypto, has raised $11.5 million in a Series A round led by Pantera, with participation from Coinbase Ventures, Wintermute Ventures and Karatage. The company plans to use the fresh capital to expand into new markets and build out its onchain financial infrastructure. Launched eight months ago, the platform combines perpetuals trading, prediction markets, and real-world crypto spending into a single interface built natively on Hyperliquid's execution environment.BioSpaceThird quarter 2025 update: IBA is highly confident to meet FY2025 guidance, and strengthens financing structureIBA (Ion Beam Applications SA) reported Q3 2025 business results with equipment order intake of €195 million (+6% YoY), confirmed FY2025 REBIT guidance of at least €25 million, and closed a €125 million refinancing club deal with Belgian and international banks. The company has €1.3 billion backlog stable and completed the acquisition of Berlin-based PhantomX, while its PanTera joint venture broke ground on a commercial-scale Ac-225 production facility. IBA reiterated mid-term outlook of 5-7% revenue CAGR and ~10% REBIT margin by 2028, while monitoring geopolitical risks including US tariffs and Chinese market restrictions.GlobeNewswireCleanCore Solutions (NYSE: ZONE) Announces $175,000,420 Private Placement to Build the Official Dogecoin Treasury Founded by the Dogecoin Foundation and the House of Doge, Inc.CleanCore Solutions announced a private placement of 175,000,420 pre-funded warrants at $1 each, raising about $175 million to build a Dogecoin treasury. The treasury is sponsored by the Dogecoin Foundation and House of Doge, with over 80 institutional investors including Pantera and GSR. Closing is expected September 4, 2025, with Dogecoin as the primary reserve asset.